Primary Pharmaceutical Production & Drug Formulation

0.0(0)
Studied by 0 people
call kaiCall Kai
learnLearn
examPractice Test
spaced repetitionSpaced Repetition
heart puzzleMatch
flashcardsFlashcards
GameKnowt Play
Card Sorting

1/39

flashcard set

Earn XP

Description and Tags

Flashcards covering primary pharmaceutical production, unit operations, excipient functionality, release mechanisms, scale-up yield calculations, and formulation development.

40 Terms

1
New cards

What is the fundamental distinction highlighted between an API and a finished drug product?

A drug is not just an API; manufacturing must create the API, convert it into a usable dosage form, and consistently deliver the correct dose at the correct release rate.

2
New cards

What are the three stages summarized in the manufacturing concept API→PRODUCT→PATIENT\text{API} \rightarrow \text{PRODUCT} \rightarrow \text{PATIENT}?

Primary production creates the API, formulation and secondary production convert it into a dosage-form product, which is then administered to the patient.

3
New cards

In pharmaceutical manufacturing, what is the key difference between primary production and secondary production?

Primary production changes the chemical or biological material (API focus), whereas secondary production changes the dosage form (dosage-form focus).

4
New cards

What are the five steps that make up the pharmaceutical manufacturing chain?

01 Starting materials (chemicals / biological feed), 02 Primary production (make + purify API), 03 Formulation (blend API + excipients), 04 Secondary production (granulate / compress / coat), and 05 Finished product (test + pack + release).

5
New cards

Which specific unit operations are categorized under secondary production in the manufacturing chain?

Granulate, compress, and coat.

6
New cards

What are the three production routes used to manufacture Active Pharmaceutical Ingredients (APIs)?

Chemical synthesis, biotechnology, and extraction.

7
New cards

How is chemical synthesis defined for API production, and what are two examples?

Reactions build or modify molecules; examples include aspirin and ibuprofen.

8
New cards

How does biotechnology produce APIs, and what are two examples?

Cells or microorganisms produce the API; examples include antibiotics and proteins.

9
New cards

How are APIs produced via extraction, and what are two examples?

The API is isolated from natural material; examples include digoxin and heparin.

10
New cards

Whichever production route is used, what four parameters must the isolated API be controlled for?

Identity, purity, particle properties, and moisture.

11
New cards

What are the four core unit operations of primary production used to isolate a usable API?

1 Reaction, 2 Crystallisation, 3 Filtration, and 4 Drying.

12
New cards

What are the main functions of the reaction and crystallisation steps in primary production?

Reaction creates the target molecule under controlled temperature, mixing, and time; crystallisation purifies the molecule and creates crystals with a suitable size distribution.

13
New cards

What are the main functions of the filtration and drying steps in primary production?

Filtration retains the solid API while the liquid phase passes through; drying removes water or solvent to protect stability and powder flow.

14
New cards

Why is an API alone rarely suitable to be administered directly as a medicine?

The dose may be too small to handle, difficult to compress, unstable, poorly soluble, or unpleasant to take.

15
New cards

What components constitute a formulation according to the lecture equation?

Formulation=API+excipients+process choices\text{Formulation} = \text{API} + \text{excipients} + \text{process choices}

16
New cards

What is the function of a diluent, and what are two common examples?

A diluent adds bulk to the tablet; examples include lactose and MCC (microcrystalline cellulose).

17
New cards

What is the function of a binder, and what are two common examples?

A binder holds particles together; examples include povidone and starch.

18
New cards

What is the role of a disintegrant, and which specific excipient is cited as an example?

A disintegrant breaks the tablet apart; an example is croscarmellose.

19
New cards

How do glidants and lubricants differ in function, and what examples are given for each?

A glidant improves powder flow (e.g., colloidal silica), whereas a lubricant reduces friction during processing (e.g., magnesium stearate).

20
New cards

What is the role of a coating, and what examples of coating polymers are mentioned?

A coating protects the core or controls release; examples include HPMC and enteric polymers.

21
New cards

In the worked paracetamol tablet example, what is the API strength and the total tablet weight?

The tablet strength is 500.0 mg500.0\,\text{mg} of paracetamol (API), and the total tablet weight is 680.5 mg680.5\,\text{mg}.

22
New cards

How is the drug load of the paracetamol tablet calculated?

500.0 mg680.5 mg×100%=73.5%\frac{500.0\,\text{mg}}{680.5\,\text{mg}} \times 100\% = 73.5\%

23
New cards

In the paracetamol tablet example, what are the specific quantities of microcrystalline cellulose and magnesium stearate per tablet?

Microcrystalline cellulose is 89.0 mg/tablet89.0\,\text{mg/tablet} and magnesium stearate is 6.0 mg/tablet6.0\,\text{mg/tablet}.

24
New cards

What three major categories of factors control drug bioavailability?

Physiological factors (GI pH, food, gastric emptying), physicochemical factors (pKapK_a, solubility, stability, particle size), and dosage form factors (excipients, process, release system).

25
New cards

How do decreasing API particle size and increasing disintegrant levels alter tablet performance?

Decreasing API particle size increases total surface area leading to faster dissolution, while increasing disintegrants accelerates tablet breakup leading to faster release.

26
New cards

How do increasing hydrophobic lubricant and applying an enteric coating alter drug release?

Increasing hydrophobic lubricant causes less wetting and slower release, whereas applying an enteric coating resists stomach acid to provide delayed release.

27
New cards

What characterizes an immediate-release dosage form?

Rapid disintegration and dissolution providing fast onset, though it may require repeated dosing.

28
New cards

What characterizes an extended-release dosage form?

The API is released over a longer period, maintaining therapeutic drug levels with fewer doses.

29
New cards

What is a delayed-release dosage form, and what clinical precaution applies to modified-release products?

Drug release starts later (often after passing the stomach) via an enteric coating responding to GI conditions; modified-release products should not be crushed or split unless the label specifically allows it.

30
New cards

What are the four major quality attributes evaluated to verify that a drug meets standards until shelf-life expiry?

Correct dose (assay, content uniformity), mechanical quality (hardness, friability, appearance), reproducible release (disintegration, dissolution), and safety and stability (microbial limits, degradants).

31
New cards

What are the four main stability stresses that can degrade a drug product during shelf life?

Heat, moisture, light, and oxygen.

32
New cards

For a batch of 500,000500{,}000 tablets with a tablet weight of 680.5 mg680.5\,\text{mg}, what is the theoretical batch mass?

680.5 mg×500,000=340.25 kg680.5\,\text{mg} \times 500{,}000 = 340.25\,\text{kg}

33
New cards

If the theoretical batch mass is 340.25 kg340.25\,\text{kg} and actual collection after tableting is 331.3 kg331.3\,\text{kg}, what are the percentage yield and process loss?

% yield=331.3 kg340.25 kg×100%=97.4%\text{\% yield} = \frac{331.3\,\text{kg}}{340.25\,\text{kg}} \times 100\% = 97.4\%, which corresponds to a process loss of 2.6%2.6\%.

34
New cards

What is continuous manufacturing, and which ICH guideline provides its harmonised regulatory framework?

Connected unit operations run with continuous material flow, governed by the ICH Q13 framework for development, control, and lifecycle management.

35
New cards

What two examples of new dosage-form technologies are cited from the FDA's emerging technology program?

3D printing and ultra-long-acting oral formulations.

36
New cards

Why can a chemically pure API still perform poorly in drug formulation?

Physical properties matter: crystal form (polymorph and hydration state), particle size (flow, mixing, dissolution), residual solvent, and moisture can undermine performance even if chemical purity is high.

37
New cards

What five parameters do operators control during the crystallisation unit operation?

1 Supersaturation (driving force), 2 Cooling profile, 3 Seeding (promotes controlled nucleation), 4 Agitation (influences mixing and crystal breakage), and 5 Solvent choice (affects solubility and impurity rejection).

38
New cards

What is the sequence of downstream problems caused by generating too many fine crystals during crystallisation?

Too many fine crystals →\rightarrow slow filtration →\rightarrow longer drying →\rightarrow variable powder.

39
New cards

What are the five key process variables in the reaction step, and what rule governs the reaction endpoint?

Temperature, mixing, addition rate, reaction time, and pH / composition; the reaction endpoint should always be based on evidence rather than simply elapsed time.

40
New cards

What are the five steps in the structured formulation development cycle?

1 Understand the API, 2 Define the target, 3 Select excipients, 4 Prepare prototypes, and 5 Evaluate performance (iteratively refining until quality targets are met).